Table 1 Clinicopathological characteristics of HGSOC patient cohort
Characteristics | Discovery cohort | Validation cohort | ||
|---|---|---|---|---|
Sensitive No. (%) | Resistant No. (%) | Sensitive No. (%) | Resistant No. (%) | |
All cases | 7 | 7 | 25 | 19 |
Median Age, years (range) | 55 (48–65) | 62 (47–71) | 59 (37–73) | 59 (32–79) |
FIGO Stage | ||||
 III | 6 (85.7) | 6 (85.7) | 22 (88.0) | 14 (73.7) |
 IV | 1 (14.3) | 1 (14.3) | 3 (12.0) | 5 (26.3) |
Primary treatment strategy | ||||
 PDS | 7 (100) | 6 (85.7) | 20 (80.0) | 8 (42.1) |
 NACT+IDS | – | – | 5 (20.0) | 9 (47.4) |
 NACT | – | 1 (14.3) | – | 2 (10.5) |
Primary chemotherapy | ||||
 Platinum/Paclitaxel | 2 (28.6) | 4 (57.1) | 11 (44.0) | 11 (57.9) |
 Platinum/Paclitaxel/Bevacizumab | 5 (71.4) | 3 (42.9) | 14 (56.0) | 8 (42.1) |
Residual tumor at surgery | ||||
 RT = 0 | 5 (71.4) | 4 (57.1) | 17 (68.0) | 10 (52.6) |
 RT > 0 | 1 (14.3) | 2 (28.6) | 5 (20.0) | 5 (26.3) |
 Not available/applicable | 1 (14.3) | 1 (14.3) | 3 (12.0) | 4 (21.1) |